PROTEOMICS

这一共享资源的目标是为研究人员提供具有成本效益的最先进的仪器，以及蛋白质组学分析的专业知识，目标是识别新的蛋白质生物标志物，用于癌症的预防、诊断和治疗。由于蛋白质通过翻译后修饰（PTMs）、分泌、RNA剪接等多种途径表现出极大的多样性，加之其广泛的动态表达范围，目前尚不存在单一的平台来对蛋白质的全局表达进行差异性分析。因此，这个共享资源项目结合并整合了由Dean P. Edwards博士领导的单个组织单元下的几个不同学院联合主任的仪器和专业知识。通过该机构和丹·l·邓肯癌症中心在设备、新员工的启动工资和运营支持方面的170万美元的联合投资，蛋白质组学共享资源（PSR）扩大了其技术能力和服务，并迅速发展成为癌症中心使用最多的资源之一。PSR目前由四位联合主任（秦军博士、Richard Cook博士、黄世霞博士、梁伊斯特伍德博士）和六位训练有素的技术人员组成。自2006年提交CCSG以来，开发的新技术和服务包括基于非质谱的蛋白质分析平台，如Luminex荧光珠系统、二维液体和凝胶电泳以及抗体/肽阵列；质谱鉴定和PTM分析从细胞中分离的内源性蛋白质复合物，定量质谱分析蛋白质的SILAC（稳定同位素标记与细胞中的重氨基酸）和提高通量生产

The goal of this shared resource is to provide investigators with cost effective state-of-the-art instrumentation, and specialized expertise for analysis of proteomes with the goal of identifying novel protein biomarkers with applications for prevention, diagnosis and treatment of cancer. Because of the extremely diverse nature of proteins through post-translation modifications (PTMs), secretion, and RNA splicing coupled with their wide dynamic range of expression, no single platform exists for differential analysis of global protein expression. This Shared Resource therefore combines and integrates the instrumentation and expertise of several different faculty co-directors under a single organizational unit directed by Dr. Dean P. Edwards. Through a combined investment by the Institution and the Dan L. Duncan Cancer Center of $1.7M in equipment, start-up salary for new staff and operational support, the Proteomics Shared Resource (PSR) has expanded its technological capabilities and services and has grown tremendously to become one of the heaviest utilized Resources of the Cancer Center. The PSR is currently staffed by four co-directors (Drs Jun Qin, Richard Cook, Shixia Huang, Eastwood Leung) and six highly trained technical staff. New technologies and services developed since the CCSG submission in 2006 include non-mass spectrometry-based protein profiling platforms such as the Luminex fluorescence bead system, two dimensional liquid and gel electrophoresis and antibody/peptide arrays; mass spectrometry identification and PTM analysis of endogenous protein complexes isolated from cells, quantitative mass spectrometry protein profiling by SILAC (stable isotope labeling with heavy amino acids in cells) and enhanced throughput production of monoclonal antibodies (MAbs). These new technologies and services, together with the previously established technologies of protein chemistry, MALDI-TOF identification and PTM analysis of proteins, baculovirus expression of recombinant proteins and conventional hybridoma/MAb production, have created a highly comprehensive Proteomic Shared Resource capable of facilitating both protein biomarker discovery research and translational validation studies through custom antibody production. We will continue to expand and meet the needs of the Cancer Center through shared instrument grant applications and by providing expertise and new leading edge proteomic technologies as the field rapidly evolves.